The drug met its primary endpoints in a Chinese trial, while a Phase III trial in Sjögren's syndrome is currently underway in ...

Phase 3 results position telitacicept as potential best-in-disease profile in primary Sjögren's disease Telitacicept ...

Amgen Inc (($AMGN)) announced an update on their ongoing clinical study. Amgen Inc. is conducting a Phase 3 study titled ‘A Phase 3 Randomized, ...

Novartis may have abandoned one Sjögren's syndrome asset this year, but it looks like the drugmaker has a winner on its hands ...

Novartis is hoping to gain approval for its Sjögren’s disease drug after it met the endpoints in two Phase III trials. The ...

China-based RemeGen has announced that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion protein drug, ...

The China-based phase 3 trial of telitacicept in primary Sjögren's syndrome (pSS) met its primary endpoint, which focused on ...

The drug, ianalumab, met its objectives in two Phase 3 studies in Sjögren’s syndrome, boosting the outlook of a ...

Yantai-based RemeGen said it will now move ahead with filing telitacicept with China's National Medical Products ...

References 1. Kang Z, Du Y, Cui R, et al. Psoriasis increases the risk of Sjögren's syndrome: evidence from a propensity score-matched cohort study and transcriptomic analysis.

Sjögren’s syndrome is a chronic, systemic autoimmune disease affecting exocrine glands, primarily the salivary and tear glands, with severe cases affecting multiple organs.

The ability to identify the features of Sjögren’s syndrome, and to seek payer approval for specific manifestations of the disease, is of paramount importance for the rheumatologist, according ...